PARP Inhibitor Shows Promise in Patients With BRCA-Mutated Pancreatic Cancer

By The ASCO Post
Posted: 5/23/2018 2:30:07 PM
Last Updated: 5/23/2018 3:23:34 PM

Key Points

Of the 19 patients treated, 4 had responses and 2 additional patients had stable disease.
The objective confirmed response rate, the primary endpoint for the study, was 16% (3/19).
About 9% of patients have BRCA1/2mutation–associated pancreatic cancer.